Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

JAK2 inhibitor BS HH 002.SA

A derivative of the cytotoxic plant alkaloid homoharringtonine (HHT) and an inhibitor of Janus-associated kinase 2 (JAK2), with potential antineoplastic activity. Upon administration, JAK2 inhibitor BS HH 002.SA inhibits JAK2 activity, thereby preventing the activation of the JAK/signal transducer and activator of transcription (STAT) signaling pathway and the activation of STAT3 and STAT5. This may lead to an induction of tumor cell apoptosis and a decrease in tumor cell proliferation. JAK2, often upregulated or mutated in a variety of cancer cells, mediates STAT3 activation and plays a key role in tumor cell proliferation and survival.
Code name:BS HH 002.SA
BS-HH-002.SA
HH-002
Search NCI's Drug Dictionary